Neurol. pro Praxi, 2007; 2: 76-78

Nežádoucí účinky nových antiepileptik

MUDr. Ivana Tyrlíková, MUDr. Milan Brázdil, Ph.D.
I. neurologická klinika LF MU a FN u sv. Anny Brno

Práce pojednává o nežádoucích účincích antiepileptik. Zpracovává data a závěry z 20 reprezentativních epidemiologických studií a metaanalýz o nežádoucích účincích nových antiepileptik. Klade si za cíl syntetizovat z těchto pramenů základní přehled o známých rizicích antiepiletik. Vzhledem k různorodosti metodologických přístupů i výzkumných souborů nebylo možno jednotlivá antiepileptika vzájemně porovnávat.

Keywords: nová antiepileptika, nežádoucí účinky

Published: July 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Tyrlíková I, Brázdil M. Nežádoucí účinky nových antiepileptik. Neurol. praxi. 2007;8(2):76-78.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Bauer J, Ben-Menachem E, Kramer G, Fryze W, Da Silva S, Kasteleijn-Nolst Trenité DGA. Levetiracetam: a long-term follow-up study of efficacy and safety. Acta Neurol Scand. 114, 2006; 169-176. Go to original source... Go to PubMed...
    2. Ben-Zeev B, Watemberg N, Augarten A, Brand N, Yahav Y, Efrati O, Topper L, Blatt I. Oligohydrosis and hyperthermia: pilot study of a novel topiramate adverse effect. J Child Neurol. 2003;18 (4): 254-257. Go to original source... Go to PubMed...
    3. Brodie MJ. Pregabalin As Adjunctive Therapy for Partial Seizures. Epilepsia, 2004, vol. 45: 19-27. Go to original source... Go to PubMed...
    4. Curry WJ, Kulling DL. Newer antiepileptic drugs. American Family Physician 1998 57; 3.
    5. Douglas FL, Devinsky O. Psychiatric adverse events during vigabatrin therapy. Neurology, 1999; 53: 1503. Go to original source... Go to PubMed...
    6. Chaves J, Sander JW. Seizure aggravation in idiopathic generalized epilepsies. Epilepsia, 2005 46 (9) 133-139. Go to original source... Go to PubMed...
    7. Fraunfelder F, Fraunfelder F, Keates E.Topiramate-associated acute, bilateral, secondary angle-closure glaucoma. Ophthalmology, Volume 111, Issue 1, Pages 109-111.
    8. French J, Edrich P, Frajer JA. A systematic review of the safety profile of levetiracetam:A new antiepileptic drug. Epilepsy Res., 2001/11, 47 (1-2): 77-90. Go to original source... Go to PubMed...
    9. Harden C. Safety profile of levetiracetam. In. Leppic E. Editor. Pharmacological treatment of epilepsy: Current trade-off and the role of levetiracetam. Epilepsia 2001, 42 suppl. 4: 36-39.
    10. Chmielewska B, Stelmasiak Z, Clinical evaluation of Gabitril and Lamictal for drug resistant epilepsy in adults. Ann Univ Mare Curie Sklodovska, 2001, 56: 35-42.
    11. Kalviainen R, Long-Term Safety of Tiagabine. Epilepsia, 2004, vol. 42., 46-48. Go to original source...
    12. Kalviainen R, Matzjarvi M, Nikoskelainen E, Partanen J, Partanen K, Riekkinen P. Vigabatrin, a gabaergic antiepileptic drug, causes concentric visual field defect. Neurology, 1999; 53: 922. Go to original source... Go to PubMed...
    13. Leppik IE. Tiagabine: the safety landscape, Epilepsia,1995, 36 (supl. 6). 10-13. Go to original source... Go to PubMed...
    14. Martin R, Kuzniecky R, Ho S, Hetherington H, Pan J, Sinclair K, Gilliam F, Faught E. Cognitive effects of topiramate, gabapentin, and lamotrigine in healthy young adults. Neurology, 1999, 52, 321-327. Go to original source... Go to PubMed...
    15. Pande AC, Feltner DE, Jefferson JW, et al. Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study. J Clin Psychopharmacol. 2004; 24: 141-149. Go to original source... Go to PubMed...
    16. Shorvon S, Safety of Topiramate: Averse Events and Relationships to Dosing.Epilepsia, 1996, 38 Suppl 1: 45-51. Go to original source... Go to PubMed...
    17. Tatum WO, French JA, Faught E, Morris GL, Liporace J, Kanner A, Goff SL, Winters L, Fix A. Postmarketing Experience with Topiramate and Cognition. Epilepsia, 2001, 42 (9): 1134-1140. Go to original source... Go to PubMed...
    18. Schmitz B, Psychiatric Syndromes Related to Antiepileptic Drugs. Epilepsia, 40, 1999, (supl. 10), 65-70. Go to original source... Go to PubMed...
    19. White JR, Walczak TS, Leppik IE, Rarick J, Tran T, Beniak TE, Matchinsky DJ, Gumnit RJ. Discontinuation of levetiracetam because of behavioral side effects. Neurology 2003; 61: 1218-1221. Go to original source... Go to PubMed...
    20. Wong ICK, Lhatto SD. Averse Reactions to New Anticonvulsant Drugs. Drug Safety, 2000, 23 (1), 35-56. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.